Jean-François Formela, M.D.


Jean-François Formela is a partner and focuses on novel drug discovery approaches and therapeutics. He joined Atlas Venture in 1993 to build the U.S. life sciences franchise. He is a director and co-founder of IFM Therapeutics, Intellia Therapeutics (NASDAQ: NTLA), Korro Bio, and Triplet Therapeutics. Jean-François also serves on the boards of Ikena Oncology (NASDAQ: IKNA), Scorpion Therapeutics and Spero Therapeutics (NASDAQ: SPRO). Some of his prior investments include Arteaus Therapeutics (acquired by Eli Lilly), CoStim Pharmaceuticals (acquired by Novartis), Exelixis (NASDAQ: EXEL) and Translate Bio (NASDAQ: TBIO, acquired by Sanofi). Jean-François received his M.D. from Paris University School of Medicine and his M.B.A. from Columbia University.

Scroll to Top